Illumina Inc. saw a price increase of 3.47%, reaching a 20-day high amid positive market conditions, with the Nasdaq-100 up 0.83% and the S&P 500 up 0.58%.
This surge is attributed to the launch of Illumina's Connected Multiomics platform, which integrates multiomic data to accelerate biological research. The platform's user-friendly design, based on feedback from early access users, allows researchers to easily analyze complex biological data, enhancing the efficiency of discoveries in precision medicine. The incorporation of AI capabilities further drives breakthroughs in biology and drug development.
The introduction of this innovative platform positions Illumina favorably in the competitive landscape of biological research tools, potentially leading to increased adoption and revenue growth as researchers seek advanced solutions for their studies.
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
3 Sell
Hold
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
TD Cowen
Hold
maintain
$115 -> $140
Al Analysis
2026-01-07
Reason
TD Cowen
Price Target
$115 -> $140
Al Analysis
2026-01-07
maintain
Hold
Reason
TD Cowen raised the firm's price target on Illumina to $140 from $115 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Guggenheim
Buy
maintain
$114 -> $144
2026-01-05
Reason
Guggenheim
Price Target
$114 -> $144
2026-01-05
maintain
Buy
Reason
Guggenheim raised the firm's price target on Illumina to $144 from $114 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ILMN
Unlock Now
Evercore ISI
Vijay Kumar
Outperform
maintain
$142 -> $155
2026-01-05
Reason
Evercore ISI
Vijay Kumar
Price Target
$142 -> $155
2026-01-05
maintain
Outperform
Reason
Evercore ISI analyst Vijay Kumar raised the firm's price target on Illumina to $155 from $142 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Canaccord
Kyle Mikson
Hold
maintain
$112 -> $130
2025-12-22
Reason
Canaccord
Kyle Mikson
Price Target
$112 -> $130
2025-12-22
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Illumina to $130 from $112 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. Among their covered companies, they see a key catalyst in 2026 for Illumina with its AXELIOS luanch with Roche Holdings.
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
